{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:22:04Z","timestamp":1792034524650,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the high morbidity and severe consequences of epidermolysis bullosa (EB), current treatments remain inadequate, lacking efficacy and the ability to target the microbial and inflammatory components of EB wounds. In this first-in-human open-label, single-arm study\u2014part 3 of a 3-part Phase 1 clinical trial\u2014we examined the safety, tolerability, and systemic exposure of topically applied TCP-25, a thrombin-derived C-terminal peptide with demonstrated anti-inflammatory, antimicrobial, and wound-healing properties in murine and porcine infection models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five patients with inherited recessive dystrophic EB received TCP-25 gel, applied to a 50-cm\n                      <jats:sup>2<\/jats:sup>\n                      primary wound treatment area, which was compared with a reference wound treatment area which received standard wound care alone. TCP-25 gel was also applied to a 50-cm\n                      <jats:sup>2<\/jats:sup>\n                      secondary wound treatment area of a higher age or in a more complicated area. TCP-25 gel was administered at escalating doses of 7.25\u2009mg, 14.5\u2009mg, 21.5\u2009mg, and 43.0\u2009mg, 3 times per week over 4 consecutive 1-week treatment periods. For the primary safety endpoint, 11 adverse events were recorded, 10 unlikely related to treatment and mild or moderate in severity, with one possibly linked to gel adhesion. Additionally, no abnormal local reactions were observed in any wound treated with TCP-25, nor in any reference wound, compared to expected wound healing outcomes. For the secondary endpoint, we did not observe any systemic plasma uptake of TCP-25 in any participant. In an exploratory analysis, we observed a steady reduction in open wound size in TCP-25-treated primary wounds, culminating in a median reduction of 76% from baseline to Day 29. Reference wounds exhibited variable changes in wound size, including some increases in size at earlier time points. Secondary wounds that were treated with TCP-25 also decreased steadily, reaching a median open wound size reduction of 78% on day 29. Additionally, TCP-25 demonstrated potential efficacy in accelerating wound healing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Topical TCP-25 gel was safe and well tolerated and showed no systemic uptake in patients with dystrophic EB, demonstrating promising effects on wound healing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      Clinical trial NCT05378997 was registered 2022\u201305-12 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05378997\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT05378997<\/jats:ext-link>\n                      ) and amended 2024\u201302-12 to include Part-3 on dystrophic EB. The amendment was prospectively registered at EudraCT (2021-004728-14).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04156-7","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T02:34:58Z","timestamp":1764642898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Results of a non-randomized, open-label phase I study evaluating the novel immunomodulatory peptide TCP-25 for treatment of dystrophic epidermolysis bullosa"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-1450","authenticated-orcid":false,"given":"Karl","family":"Wallblom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Holmgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Belfrage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torborg","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Hugerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Karin","family":"Lindqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enik\u00f6","family":"Sonkoly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Schmidtchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"1","key":"4156_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine J-D, Harper N, Has C, et al. Epidermolysis bullosa. Nat Rev Disease Primers. 2020;6(1):78.","journal-title":"Nat Rev Disease Primers"},{"issue":"3","key":"4156_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jdermsci.2021.11.004","volume":"104","author":"K Natsuga","year":"2021","unstructured":"Natsuga K, Shinkuma S, Hsu CK, Fujita Y, Ishiko A, Tamai K, et al. Current topics in epidermolysis bullosa: pathophysiology and therapeutic challenges. J Dermatol Sci. 2021;104(3):164\u201376.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"4156_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614\u201327.","journal-title":"Br J Dermatol"},{"issue":"1","key":"4156_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","volume":"15","author":"AL Bruckner","year":"2020","unstructured":"Bruckner AL, Losow M, Wisk J, Patel N, Reha A, Lagast H, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4156_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jpeds.2007.06.039","volume":"152","author":"JD Fine","year":"2008","unstructured":"Fine JD, Johnson LB, Weiner M, Suchindran C. Cause-specific risks of childhood death in inherited epidermolysis bullosa. J Pediatr. 2008;152(2):276\u201380.","journal-title":"J Pediatr"},{"issue":"2","key":"4156_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.det.2010.01.004","volume":"28","author":"JE Mellerio","year":"2010","unstructured":"Mellerio JE. Infection and colonization in epidermolysis bullosa. Dermatol Clin. 2010;28(2):267\u201369, ix.","journal-title":"Dermatol Clin"},{"key":"4156_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2017.11.004","volume":"66","author":"MC Foll","year":"2018","unstructured":"Foll MC, Fahrner M, Gretzmeier C, Thoma K, Biniossek ML, Kiritsi D, et al. Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas. Matrix Biol. 2018;66:1\u201321.","journal-title":"Matrix Biol"},{"issue":"8","key":"4156_CR8","first-page":"1365","volume":"11","author":"D Bonamonte","year":"2022","unstructured":"Bonamonte D, Filoni A, De Marco A, Lospalluti L, Nacchiero E, Ronghi V, et al. Squamous cell carcinoma in patients with inherited epidermolysis Bullosa. Rev Curr Lit. Cells. 2022;11(8):1365.","journal-title":"Rev Curr Lit. Cells"},{"issue":"11","key":"4156_CR9","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jid.2017.07.002","volume":"137","author":"V Alexeev","year":"2017","unstructured":"Alexeev V, Salas-Alanis JC, Palisson F, Mukhtarzada L, Fortuna G, Uitto J, et al. Pro-inflammatory chemokines and cytokines dominate the blister fluid molecular signature in patients with epidermolysis Bullosa and affect leukocyte and stem cell migration. J Invest Dermatol. 2017;137(11):2298\u2013308.","journal-title":"J Invest Dermatol"},{"key":"4156_CR10","doi-asserted-by":"crossref","unstructured":"Onoufriadis A, Proudfoot LE, Ainali C, Torre D, Papanikolaou M, Rayinda T, et al. Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing. Exp Dermatol. 2021.","DOI":"10.1111\/exd.14481"},{"issue":"4","key":"4156_CR11","doi-asserted-by":"publisher","first-page":"E705","DOI":"10.1073\/pnas.1709111115","volume":"115","author":"A Nystrom","year":"2018","unstructured":"Nystrom A, Bornert O, Kuhl T, Gretzmeier C, Thriene K, Dengjel J, et al. Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa. Proc Natl Acad Sci U S A. 2018;115(4):E705\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"4156_CR12","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1111\/exd.14411","volume":"30","author":"L Huitema","year":"2021","unstructured":"Huitema L, Phillips T, Alexeev V, Igoucheva O. Immunological mechanisms underlying progression of chronic wounds in recessive dystrophic epidermolysis bullosa. Exp Dermatol. 2021;30(12):1724\u201333.","journal-title":"Exp Dermatol"},{"issue":"1","key":"4156_CR13","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1038\/ncomms6932","volume":"6","author":"E Hoste","year":"2015","unstructured":"Hoste E, Arwert EN, Lal R, South AP, Salas-Alanis JC, Murrell DF, et al. Innate sensing of microbial products promotes wound-induced skin cancer. Nat Commun. 2015;6(1):5932.","journal-title":"Nat Commun"},{"issue":"7","key":"4156_CR14","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/ced.14592","volume":"46","author":"J Bar","year":"2021","unstructured":"Bar J, Sarig O, Lotan-Pompan M, Dassa B, Miodovnik M, Weinberger A, et al. Evidence for cutaneous dysbiosis in dystrophic epidermolysis bullosa. Clin Exp Dermatol. 2021;46(7):1223\u201329.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"4156_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1525-1470.2009.01070.x","volume":"27","author":"HA Brandling-Bennett","year":"2010","unstructured":"Brandling-Bennett HA, Morel KD. Common wound colonizers in patients with epidermolysis bullosa. Pediatr Dermatol. 2010;27(1):25\u201328.","journal-title":"Pediatr Dermatol"},{"issue":"11","key":"4156_CR16","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/j.jid.2018.04.026","volume":"138","author":"I Fuentes","year":"2018","unstructured":"Fuentes I, Guttmann-Gruber C, Tay ASL, Pi\u00f1\u00f3n Hofbauer J, Denil SLIJ, Reichelt J, et al. Reduced microbial diversity is a feature of recessive dystrophic epidermolysis Bullosa-involved skin and wounds. J Invest Dermatol. 2018;138(11):2492\u201395.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"4156_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/pde.14444","volume":"38","author":"LE Levin","year":"2021","unstructured":"Levin LE, Shayegan LH, Lucky AW, Hook KP, Bruckner AL, Feinstein JA, et al. Characterization of wound microbes in epidermolysis bullosa: results from the epidermolysis bullosa clinical characterization and outcomes database. Pediatr Dermatol. 2021;38(1):119\u201324.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"4156_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/pde.13331","volume":"35","author":"HM Singer","year":"2018","unstructured":"Singer HM, Levin LE, Garzon MC, Lauren CT, Planet PJ, Kittler NW, et al. Wound culture isolated antibiograms and caregiver-reported skin care practices in children with epidermolysis bullosa. Pediatr Dermatol. 2018;35(1):92\u201396.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"4156_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijmm.2013.11.012","volume":"304","author":"van der Kooi-Pol Mm","year":"2014","unstructured":"van der Kooi-Pol Mm, Duipmans JC, Jonkman MF, van Dijl JM. Host-pathogen interactions in epidermolysis bullosa patients colonized with staphylococcus aureus. Int J Med Microbiol. 2014;304(2):195\u2013203.","journal-title":"Int J Med Microbiol"},{"issue":"8","key":"4156_CR20","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1038\/jid.2012.208","volume":"132","author":"MR Dasu","year":"2012","unstructured":"Dasu MR, Isseroff RR. Toll-like receptors in wound healing: location, accessibility, and timing. J Invest Dermatol. 2012;132(8):1955\u201358.","journal-title":"J Invest Dermatol"},{"key":"4156_CR21","doi-asserted-by":"publisher","first-page":"76\u2013","DOI":"10.1186\/1750-1172-9-76","volume":"9","author":"M El Hachem","year":"2014","unstructured":"El Hachem M, Zambruno G, Bourdon-Lanoy E, Ciasulli A, Buisson C, Hadj-Rabia S, et al. Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa. Orphanet J Rare Dis. 2014;9:76\u2013.","journal-title":"Orphanet J Rare Dis"},{"key":"4156_CR22","unstructured":"Jpe D, Clapham J. Best practice guidelines for skin and wound care in epidermolysis bullosa. An Int Consensus. 2017."},{"issue":"10","key":"4156_CR23","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/exd.13979","volume":"28","author":"C Prodinger","year":"2019","unstructured":"Prodinger C, Reichelt J, Bauer JW, Laimer M. Epidermolysis bullosa: advances in research and treatment. Exp Dermatol. 2019;28(10):1176\u201389.","journal-title":"Exp Dermatol"},{"key":"4156_CR24","unstructured":"Banerjee S, Argaez C. Topical antibiotics for infection prevention: a review of the clinical effectiveness and guidelines. Topical antibiotics for infection prevention: a review of the clinical effectiveness and guidelines. CADTH Rapid Response Rep. Ottawa (ON):CADTH;2017."},{"issue":"8","key":"4156_CR25","doi-asserted-by":"publisher","first-page":"8069","DOI":"10.3390\/ijerph110808069","volume":"11","author":"EE Creppy","year":"2014","unstructured":"Creppy EE, Diallo A, Moukha S, Eklu-Gadegbeku C, Cros D. Study of epigenetic properties of Poly(HexaMethylene Biguanide) hydrochloride (PHMB). Int J Environ Res Public Health. 2014;11(8):8069\u201392.","journal-title":"Int J Environ Res Public Health"},{"key":"4156_CR26","unstructured":"Filsuvez Gel, summary of product characteristics (SmPC) updated 18-aug-2022. Amryt Pharmaceuticals DAC."},{"issue":"4","key":"4156_CR27","doi-asserted-by":"publisher","first-page":"e1000857","DOI":"10.1371\/journal.ppat.1000857","volume":"6","author":"P Papareddy","year":"2010","unstructured":"Papareddy P, Rydeng\u00e5rd V, Pasupuleti M, Walse B, M\u00f6rgelin M, Chalupka A, et al. Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog. 2010;6(4):e1000857.","journal-title":"PLoS Pathog"},{"issue":"1","key":"4156_CR28","doi-asserted-by":"publisher","first-page":"13136","DOI":"10.1038\/s41598-017-13197-3","volume":"7","author":"R Saravanan","year":"2017","unstructured":"Saravanan R, Adav SS, Choong YK, van der Plas MJA, Petrlova J, Kjellstrom S, et al. Proteolytic signatures define unique thrombin-derived peptides present in human wound fluid in vivo. Sci Rep. 2017;7(1):13136.","journal-title":"Sci Rep"},{"issue":"524","key":"4156_CR29","doi-asserted-by":"publisher","first-page":"eaax6601","DOI":"10.1126\/scitranslmed.aax6601","volume":"12","author":"M Puthia","year":"2020","unstructured":"Puthia M, Butrym M, Petrlova J, Str\u00f6mdahl A-C, Andersson M\u00c5, Kjellstr\u00f6m S, et al. A dual-action peptide-containing hydrogel targets wound infection and inflammation. Sci Transl Med. 2020;12(524):eaax6601.","journal-title":"Sci Transl Med"},{"issue":"1","key":"4156_CR30","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1038\/s41467-018-05242-0","volume":"9","author":"R Saravanan","year":"2018","unstructured":"Saravanan R, Holdbrook DA, Petrlova J, Singh S, Berglund NA, Choong YK, et al. Structural basis for endotoxin neutralisation and anti-inflammatory activity of thrombin-derived C-terminal peptides. Nat Commun. 2018;9(1):2762.","journal-title":"Nat Commun"},{"key":"4156_CR31","unstructured":"Dahlman A, Puthia M, Petrlova J, Schmidtchen A, Petruk G. Thrombin-derived C-terminal peptide reduces Candida-induced inflammation and infection in vitro and in vivo. Antimicrob Agents Chemother. 2021;AAC0103221."},{"issue":"1","key":"4156_CR32","doi-asserted-by":"publisher","first-page":"11201","DOI":"10.1038\/s41598-017-11464-x","volume":"7","author":"CH Lim","year":"2017","unstructured":"Lim CH, Puthia M, Butrym M, Tay HM, Lee MZY, Hou HW, et al. Thrombin-derived host defence peptide modulates neutrophil rolling and migration in vitro and functional response in vivo. Sci Rep. 2017;7(1):11201.","journal-title":"Sci Rep"},{"key":"4156_CR33","unstructured":"FDA. Orphan drug designation for treatment of epidermolysis bullosa, 25 C-terminal amino acids of human thrombin (TCP-25). 2024. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=1051824."},{"key":"4156_CR34","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher DC. Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010. 2010;8:18.","DOI":"10.1186\/1741-7015-8-18"},{"key":"4156_CR35","doi-asserted-by":"publisher","first-page":"e073725","DOI":"10.1136\/bmj-2022-073725","volume":"381","author":"DR Junqueira","year":"2023","unstructured":"Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, et al. Consort harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. Bmj. 2023;381:e073725.","journal-title":"Bmj"},{"key":"4156_CR36","doi-asserted-by":"publisher","first-page":"e076387","DOI":"10.1136\/bmj-2023-076387","volume":"383","author":"C Yap","year":"2023","unstructured":"Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, et al. Enhancing reporting quality and impact of early phase dose-finding clinical trials: consort dose-finding extension (CONSORT-DEFINE) guidance. Bmj. 2023;383:e076387.","journal-title":"Bmj"},{"key":"4156_CR37","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. Common terminology criteria for adverse events. CTCAEv. 2017;5."},{"key":"4156_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.actbio.2021.04.045","volume":"128","author":"A-C Str\u00f6mdahl","year":"2021","unstructured":"Str\u00f6mdahl A-C, Ignatowicz L, Petruk G, Butrym M, Wasserstrom S, Schmidtchen A, et al. Peptide-coated polyurethane material reduces wound infection and inflammation. Acta Biomaterialia. 2021;128:314\u201331.","journal-title":"Acta Biomaterialia"},{"key":"4156_CR39","doi-asserted-by":"crossref","unstructured":"Pai B VV, Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9\u201318.","DOI":"10.4103\/0378-6323.186500"},{"key":"4156_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejpb.2017.06.019","volume":"119","author":"S M\u00fcnch","year":"2017","unstructured":"M\u00fcnch S, Wohlrab J, Neubert RHH. Dermal and transdermal delivery of pharmaceutically relevant macromolecules. Eur J Pharm Biopharm. 2017;119:235\u201342.","journal-title":"Eur J Pharm Biopharm"},{"key":"4156_CR41","volume-title":"Center for biologics evaluation and research (CBER), Center for devices and radiological health (CDRH)","author":"U.S. Department of Health and Human Services","year":"2006","unstructured":"U.S. Department of Health and Human Services. Guidance for industry - chronic cutaneous ulcer and burn wounds \u2014 developing products for treatment In: food and Drug administration Center for Drug evaluation and research (CDER), editors.. Center for biologics evaluation and research (CBER), Center for devices and radiological health (CDRH). 2006."},{"key":"4156_CR42","unstructured":"EMA. Assessment report for REGRANEX. In: (CHMP) CfMPfHU, editor. EMA\/585612\/20102010."},{"issue":"1","key":"4156_CR43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13023-020-01435-3","volume":"15","author":"DF Murrell","year":"2020","unstructured":"Murrell DF, Paller AS, Bodemer C, Browning J, Nikolic M, Barth JA, et al. Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 essence study. Orphanet J Rare Dis. 2020;15(1):190.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4156_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1590\/S0365-05962013000200001","volume":"88","author":"VL Boeira","year":"2013","unstructured":"Boeira VL, Souza ES, Rocha Bde O, Oliveira PD, Oliveira Mde F, R\u00eago VR, et al. Inherited epidermolysis bullosa: clinical and therapeutic aspects. An Bras Dermatol. 2013;88(2):185\u201398.","journal-title":"An Bras Dermatol"},{"issue":"8","key":"4156_CR45","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4045\/tidsskr.14.1041","volume":"136","author":"H Fjeld","year":"2016","unstructured":"Fjeld H, Lingaas E. Polyhexanide - safety and efficacy as an antiseptic. Tidsskr Nor Laegeforen. 2016;136(8):707\u201311.","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"6","key":"4156_CR46","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jaad.2016.07.020","volume":"75","author":"K Saleh","year":"2016","unstructured":"Saleh K, Sonesson A, Persson K, Riesbeck K, Schmidtchen A. Can dressings soaked with polyhexanide reduce bacterial loads in full-thickness skin grafting? A randomized controlled trial. J Am Acad Dermatol. 2016;75(6):1221\u20138.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"4156_CR47","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/DSS.0000000000000364","volume":"41","author":"K Saleh","year":"2015","unstructured":"Saleh K, Schmidtchen A. Surgical site infections in dermatologic surgery: etiology, pathogenesis, and current preventative measures. Dermatologic Surg. 2015;41(5):537\u201349.","journal-title":"Dermatologic Surg"},{"key":"4156_CR48","doi-asserted-by":"crossref","unstructured":"Yu G, Baeder DY, Regoes RR, Rolff J. Predicting drug resistance evolution: insights from antimicrobial peptides and antibiotics. Proceedings of the Royal Society B: Biological Sciences. 2018(1874):20172687;285.","DOI":"10.1098\/rspb.2017.2687"},{"issue":"1","key":"4156_CR49","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1038\/s41467-019-12364-6","volume":"10","author":"R Spohn","year":"2019","unstructured":"Spohn R, Daruka L, L\u00e1z\u00e1r V, Martins A, Vidovics F, Gr\u00e9zal G, et al. Integrated evolutionary analysis reveals antimicrobial peptides with limited resistance. Nat Commun. 2019;10(1):4538.","journal-title":"Nat Commun"},{"issue":"8","key":"4156_CR50","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/mt.2015.58","volume":"23","author":"T K\u00fchl","year":"2015","unstructured":"K\u00fchl T, Mezger M, Hausser I, Handgretinger R, Bruckner-Tuderman L, Nystr\u00f6m A. High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis Bullosa. Mol Ther. 2015;23(8):1368\u201379.","journal-title":"Mol Ther"},{"issue":"24","key":"4156_CR51","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","volume":"387","author":"SV Guide","year":"2022","unstructured":"Guide SV, Gonzalez ME, Ba\u011fc\u0131 IS, Agostini B, Chen H, Feeney G, et al. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022;387(24):2211\u201319.","journal-title":"N Engl J Med"},{"issue":"10499","key":"4156_CR52","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0140-6736(25)01154-7","volume":"406","author":"CL Ebens","year":"2025","unstructured":"Ebens CL. Targeting challenging RDEB skin wounds with gene therapy. The Lancet. 2025;406(10499):106\u201308.","journal-title":"The Lancet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04156-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04156-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04156-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:52:44Z","timestamp":1781621564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04156-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4156"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04156-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was run in accordance with the most recent update of the Declaration of Helsinki, and the International Council for Harmonization E6 Good Clinical Practice guideline, following approval by the national regulatory authority (Swedish Medical Products Agency) and national ethics committee, the Swedish Ethical Review Authority (Etikpr\u00f6vningsmyndigheten, application number 2022\u201300527-01, amendment number 2023\u201305051-02). Written informed consent was provided by all participants or by their parents\/legal guardians (for those\u2009<\u200918\u2009years of age) prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS is a founder of and holds shares in in2cure AB, a parent company of Xinnate AB, which was the sponsor of the study and holds patents for TCP-25. MH and AKL are employed by Xinnate AB. The other authors declare that no conflict of interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}